U.S. markets open in 6 hours 32 minutes
  • S&P Futures

    4,229.25
    +19.25 (+0.46%)
     
  • Dow Futures

    33,407.00
    +147.00 (+0.44%)
     
  • Nasdaq Futures

    13,464.75
    +72.75 (+0.54%)
     
  • Russell 2000 Futures

    1,978.70
    +9.20 (+0.47%)
     
  • Crude Oil

    91.97
    +0.04 (+0.04%)
     
  • Gold

    1,800.50
    -13.20 (-0.73%)
     
  • Silver

    20.49
    -0.25 (-1.21%)
     
  • EUR/USD

    1.0312
    +0.0011 (+0.10%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2223
    +0.0005 (+0.04%)
     
  • USD/JPY

    132.6330
    -0.2400 (-0.18%)
     
  • BTC-USD

    24,568.94
    +1,628.27 (+7.10%)
     
  • CMC Crypto 200

    578.09
    +46.87 (+8.82%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that members of management will be presenting at and sponsoring the Telluride Retina Film Festival taking place February 3-5, 2022 in Telluride, Colorado.

As part of the event, Outlook Therapeutics will present a corporate overview. To learn more about the event, please visit tellurideretinafilmfestival.org.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com